A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT04770779 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Transfusion-dependent Alpha-Thalassemia
Transfusion-dependent Beta-Thalassemia

Interventions

DRUG: Placebo Matching Mitapivat
DRUG: Mitapivat

Sponsor

Agios Pharmaceuticals, Inc.